535 related articles for article (PubMed ID: 28257959)
1. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
3. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
5. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
6. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
7. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
[TBL] [Abstract][Full Text] [Related]
9. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
de Perrot M; Wu L; Cabanero M; Perentes JY; McKee TD; Donahoe L; Bradbury P; Kohno M; Chan ML; Murakami J; Keshavjee S; Tsao MS; Cho BCJ
J Thorac Cardiovasc Surg; 2020 May; 159(5):2082-2091.e1. PubMed ID: 31866087
[TBL] [Abstract][Full Text] [Related]
10. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
[TBL] [Abstract][Full Text] [Related]
11. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Awad MM; Jones RE; Liu H; Lizotte PH; Ivanova EV; Kulkarni M; Herter-Sprie GS; Liao X; Santos AA; Bittinger MA; Keogh L; Koyama S; Almonte C; English JM; Barlow J; Richards WG; Barbie DA; Bass AJ; Rodig SJ; Hodi FS; Wucherpfennig KW; Jänne PA; Sholl LM; Hammerman PS; Wong KK; Bueno R
Cancer Immunol Res; 2016 Dec; 4(12):1038-1048. PubMed ID: 27856426
[TBL] [Abstract][Full Text] [Related]
13. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
15. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
17. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mansour MSI; Seidal T; Mager U; Dobra K; Brunnström H; Dejmek A
Cancer Cytopathol; 2021 Jun; 129(6):468-478. PubMed ID: 33493383
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
Rrapaj E; Giacometti L; Spina P; Salvo M; Baselli GA; Veggiani C; Rena O; Trisolini E; Boldorini RL
Pathology; 2021 Jun; 53(4):462-469. PubMed ID: 33272690
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]